Synthetic Vaccine Adjuvant Shows Promise for Tuberculosis Vaccines
New data published in ImmunoHorizons identified EmT4™ as a potent adjuvant for novel Tuberculosis subunit vaccines.
ImmunoHorizons
Read More
AAI Journals Seek Section Editors
Current Editors-In-Chief for The Journal of Immunology and ImmunoHorizons tell us about the important role played by Section Editors.
OUP Partnership Offers Journal Authors Access to New Resources
The Journal of Immunology and ImmunoHorizons offers new resources through exciting publishing partnership with Oxford University Press.
Oh, The Papers We’ll Publish
Former ImmunoHorizons Editor-in-Chief Mark Kaplan has penned a final editorial title ‘Oh, The Papers We Publish’ about his experiences with…
ImmunoHorizons, Green Sunglasses, and Superheroes
Mark Kaplan, outgoing Editor-in-Chief of ImmunoHorizons, reflects on his time with the journal and where he sees open-access heading.
New Editor-in-Chief of ImmunoHorizons
AAI proudly announces the appointment of Bonnie N. Dittel, Ph.D., as the new editor-in-chief of ImmunoHorizons. Dr. Dittel’s five-year term will commence on January 1, 2025, and end on December 31, 2029.